It is also unclear whether this therapy could benefit patients with HF due to valvular heart disease, obstructive cardiomyopathy, those with Hb levels < 9.5g/dl or > 13.5g/dl and iron deficiency. Here, GSTM1 is linked to hydrops fetalis.